600671.SS SHH
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
1W: -8.8%
1M: -4.7%
3M: +21.8%
YTD: +8.0%
1Y: +46.1%
3Y: +165.4%
5Y: +164.8%
¥21.79 ($3.25)
+0.17 (+0.79%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Balance Sheet Trends
Total Assets
$441M
+27.5% ▲
5Y CAGR: -3.5%
Total Liabilities
$356M
+22.8% ▲
5Y CAGR: -2.0%
Shareholders Equity
$52M
+41.1% ▲
5Y CAGR: -12.4%
Cash & Investments
$66M
-32.9% ▼
5Y CAGR: +20.7%
Total Debt
$137M
+24.9% ▲
5Y CAGR: +9.2%
Net Debt
$71M
+500.4% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $8M | $22M | $42M | $98M | $66M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $8M | $22M | $42M | $98M | $66M |
| Net Receivables | $44M | $108M | $33M | $37M | $101M |
| Inventory | $68M | $52M | $48M | $43M | $52M |
| Other Current Assets | $103M | $108M | $3M | $4M | $2M |
| Total Current Assets | $223M | $186M | $124M | $181M | $223M |
| Property, Plant & Equip. | $200M | $200M | $165M | $152M | $193M |
| Goodwill & Intangibles | $11M | $9M | $8M | $7M | $7M |
| Long-Term Investments | $2 | $2 | $2 | $2 | $0 |
| Other Non-Current Assets | $7M | $6M | $2M | $2M | $12M |
| Total Non-Current Assets | $220M | $217M | $176M | $165M | $219M |
| Total Assets | $443M | $403M | $300M | $346M | $441M |
| — Liabilities — | |||||
| Accounts Payable | $73M | $66M | $47M | $51M | $89M |
| Short-Term Debt | $113M | $108M | $109M | $103M | $127M |
| Deferred Revenue | $65M | $77M | $4M | $0 | $0 |
| Other Current Liabilities | $49M | $3M | $58M | $57M | $16M |
| Total Current Liabilities | $252M | $251M | $221M | $220M | $286M |
| Long-Term Debt | $5M | $0 | $3M | $0 | $0 |
| Other Non-Current Liab. | $3M | $4M | $4M | $1M | $948K |
| Total Non-Current Liabilities | $97M | $87M | $74M | $70M | $70M |
| Total Liabilities | $349M | $338M | $295M | $290M | $356M |
| — Equity — | |||||
| Common Stock | $122M | $122M | $122M | $122M | $122M |
| Retained Earnings | -$136M | -$166M | -$233M | -$272M | -$256M |
| Accumulated OCI | $41M | $43M | $51M | $0 | $0 |
| Total Stockholders Equity | $73M | $45M | -$15M | $37M | $52M |
| Total Liabilities & Equity | $443M | $403M | $300M | $346M | $441M |
| — Key Metrics — | |||||
| Total Debt | $114M | $113M | $116M | $110M | $137M |
| Net Debt | $106M | $90M | $74M | $12M | $71M |
| Total Investments | $2 | $2 | $2 | $2 | $0 |